Physician profile
Manish K Zinzuvadia
NPI 1063726966
$1,256,022.95
in general payments reported to CMS, 2019-2025
20 companies · $316K in 2025
The $316K reported for 2025 was more than what 99% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $193K · 2020: $91K · 2021: $98K · 2022: $130K · 2023: $190K · 2024: $239K · 2025: $316K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $572K · Travel and Lodging: $59K · Consulting Fee: $57K · Food and Beverage: $29K · Honoraria: $27K · Education: $101.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $571,719.85 |
| Travel and Lodging | $58,916.43 |
| Consulting Fee | $57,322.00 |
| Food and Beverage | $28,988.53 |
| Honoraria | $27,225.00 |
| Education | $101.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $318,602.32 | 2019-2025 | Uzedy, Austedo Xr, Austedo |
| Alkermes, INC. | $294,968.96 | 2019-2025 | Aristada, Lybalvi, Aristada Initio |
| Otsuka America Pharmaceutical, INC. | $197,236.95 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| E.R. Squibb & Sons, L.L.C. | $159,320.72 | 2024-2025 | Cobenfy |
| Neurocrine Biosciences, INC. | $142,112.13 | 2019-2024 | Ingrezza |
| Axsome Therapeutics, INC. | $46,143.43 | 2022-2025 | Auvelity, Sunosi |
| Abbvie INC. | $41,940.52 | 2021-2025 | Vraylar |
| Luye Pharma (USA) Ltd. | $15,323.14 | 2025 | Erzofri Extended-Release |
| Allergan, INC. | $14,520.58 | 2019-2021 | |
| Idorsia Pharmaceuticals US INC | $7,134.88 | 2023 | Quviviq |
| Takeda Pharmaceuticals U.S.A., INC. | $6,986.77 | 2019-2023 | Trintellix |
| Janssen Pharmaceuticals, INC | $5,747.20 | 2019 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $2,258.85 | 2019-2025 | Abilify Asimtufii, Rexulti |
| Sunovion Pharmaceuticals INC. | $1,861.29 | 2019-2022 | |
| Lundbeck LLC | $1,093.85 | 2019-2025 | Rexulti, Abilify Asimtufii |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $633.74 | 2024-2025 | Caplyta |
| Shire North American Group INC | $47.50 | 2019 | |
| Corium, LLC | $44.82 | 2022-2023 | Azstarys |
| Bausch Health US, LLC | $24.83 | 2024 | Wellbutrin, Aplenzin |
| Avanir Pharmaceuticals, INC. | $20.47 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Manish Zinzuvadia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.